Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

Posted 1 year ago Tagged

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]

Adrian van den Hoven, Director General, Medicines for Europe

#114 What Are the Generic and Biosimilar Industries Worried About? Current Competition Law Issues Impacting the Sector.

Posted 3 years ago Tagged

Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]